CENCORA INC

Insider trading at Cencora (COR): Director Lauren M. Tyler buys hundreds of shares, signaling confidence and offering investors a fresh view on governance and future prospects.

Insider buy signals confidence in Cencora’s value‑based care model, rising earnings and tech‑driven growth—see how the board’s stake boosts shareholder value.

Discover how Cencora Inc. drives U.S. healthcare supply chains—leveraging AI, blockchain, and federal contracts to boost margins, patient access, and compliance.

Discover why Cencora Inc., a top‑fifty U.S. healthcare revenue generator, stays resilient amid market swings—its pharma focus, robust supply chain, and steady growth keep investors confident.

Discover how Cencora’s 34% growth in its employee investment plan boosts employee benefits, supports pharmacy‑distribution strategy, and improves patient access.

Explore Cencora, Inc.’s 2025 11‑K: a compliant, diversified employee‑investment plan that boosts participation, balances risk, and supports talent retention.

Read how Cencora’s partnership with Ajanta Pharma drives a 52 % jump in U.S. generics revenue and strengthens market resilience.

Corporate sponsorship by Cencora at the North Shore Animal League America Rescue Gala illustrates how pet‑care companies boost brand equity, support animal welfare, and tap growing ESG‑driven consumer demand.

Explore how Cencora Inc. (NASDAQ: CENA) grew its market cap to $55 B and saw a 57 % share price rise from 2021‑2024, outpacing peers and fueling investor confidence.

New CFO Eva Boratto leads Cencora into FY 2026, affirming stable earnings and growth while navigating value‑based reimbursement and global pricing pressures.